Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 9,550,827

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,550,827
Title:Methods for ameliorating and preventing central nervous system inflammation
Abstract: The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing or preventing schizophrenia, psychosis, delirium, e.g., post-operative delirium, drug-induced psychosis, psychotic features associated with frailty syndrome (FS), aging, depression, dementias; traumatic war neurosis, post traumatic stress disorder (PTSD) or post-traumatic stress syndrome (PTSS), Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig\'s Disease), and/or Multiple Sclerosis (MS). The invention also provides methods for purifying a C60 fullerene, C.sub.3 (tris malonic acid C60) or malonic acid derivatives.
Inventor(s): Dugan; Laura L. (Brentwood, TN), Behrens; Maria Margarita (Del Mar, CA), Ali; Sameh S. (San Diego, CA)
Application Number:12/681,743
Patent Claims:see list of patent claims

Details for Patent 9,550,827

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. ACTEMRA tocilizumab Injection 125276 2010-01-08 ⤷  Free Forever Trial 2027-10-19
Genentech, Inc. ACTEMRA tocilizumab Injection 125472 2013-10-21 ⤷  Free Forever Trial 2027-10-19
Genentech, Inc. ACTEMRA tocilizumab Injection 125472 2018-11-19 ⤷  Free Forever Trial 2027-10-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.